(Q33375805)

26 July 2017

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma (English)

1 reference

26 July 2017

1 reference

1 reference

Hans Salwender

9

0 references

Hermann Einsele

14

object named as

Hermann Einsele

1 reference

26 July 2017

Martin Kropff

1

1 reference

26 July 2017

Guido Bisping

2

1 reference

26 July 2017

Elke Schuck

3

1 reference

26 July 2017

Peter Liebisch

4

1 reference

26 July 2017

Nicola Lang

5

1 reference

26 July 2017

Markus Hentrich

6

1 reference

26 July 2017

Tobias Dechow

7

1 reference

26 July 2017

Nicolaus Kröger

8

1 reference

26 July 2017

Bernd Metzner

10

1 reference

26 July 2017

Orhan Sezer

11

1 reference

26 July 2017

Monika Engelhardt

12

1 reference

26 July 2017

Hans-Heinrich Wolf

13

1 reference

26 July 2017

Sarah Volpert

15

1 reference

26 July 2017

Achim Heinecke

16

1 reference

26 July 2017

Wolfgang E Berdel

17

1 reference

26 July 2017

Joachim Kienast

18

1 reference

26 July 2017

Deutsche Studiengruppe Multiples Myelom,

19

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

British Journal of Haematology

26 July 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 July 2017

138

1 reference

26 July 2017

3

1 reference

26 July 2017

330-337

1 reference

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Bortezomib in combination with dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Proteasome inhibition in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

Practical Bayesian guidelines for phase IIB clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06656.X

10.1111/J.1365-2141.2007.06656.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference